On February 14, 2024, Greycoat Research hosted a seminar on feline kidney disease and the role AIM played in preventing the disease.
Speakers at the seminar were Dr. Kim Jae-young, a leading member of multiple prominent animal welfare groups in Korea, and Dr. Toru Miyazaki, the world's first person to discover AIM, also known as Apoptosis Inhibitor of Macrophage.
The speakers discussed the current state of chronic kidney disease (CKD) treatment for cats, how stem cell therapy and AIM treatment could be used to treat CKD in cats, the mechanism behind AIM, the upcoming AIM Dr. Toru Protocol supplement being developed by Greycoat Research, and ways to increase lifespans of cats.
Following the lectures, Greycoat Research and the doctors invited attendees to ask any questions they had about AIM, such as its effects and potential side effects, and spent 30 minutes answering as many questions as possible.
